We rank companies based on fund manager, research analyst and news sentiment
ABUS stock icon

Arbutus Biopharma
ABUS

$2.78
1.03%
 

About: Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Employees: 73

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

125% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 8

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

29% more capital invested

Capital invested by funds: $152M [Q3] → $196M (+$44.3M) [Q4]

21% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 28

11% more funds holding

Funds holding: 94 [Q3] → 104 (+10) [Q4]

2.13% more ownership

Funds ownership: 44.71% [Q3] → 46.84% (+2.13%) [Q4]

9% more call options, than puts

Call options by funds: $3.57M | Put options by funds: $3.27M

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
44%
upside
Avg. target
$4.33
56%
upside
High target
$5
80%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
JMP Securities
Roy Buchanan
44%upside
$4
Market Outperform
Reiterated
4 Apr 2024
Chardan Capital
Keay Nakae
44%upside
$4
Buy
Reiterated
1 Mar 2024
HC Wainwright & Co.
Ed Arce
80%upside
$5
Buy
Maintained
1 Mar 2024

Financial journalist opinion